Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitis

Not Applicable

• Conditions: Type 2 diabetes mellitus with NAFLD/NASH

• Registration Number: JPRN-UMIN000018814
• Lead Sponsor: Yokohama City University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-08-28
• Study Completion: 2017-06-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

-Patients corresponding to any of the following are inapplicable -Patients with a history of allergy to any component of the study medications -Patients with severe ketosis or diabetic coma. -Patients with severe infections, perioperative status, or severe trauma -Patients with severe complications( liver disease, renal disease, mental disorder, cancer) -Patients that we may be running out of plasticity of enforcement for image or analysis of the examination, for example, remarkable spinal column scoliosis -Patients who has difficulty in MRI study implementation including having a Implantable cardioverter-defibrillator and internal metal et al -Pregnancy or lactation in women -Inadequacy of usingig this therapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified